Dialysis industry news

Stories from the dialysis comunity across the globe.

Earnings Surprise in Focus: Rockwell Medical, Inc. (NASDAQ:RMTI) - Investor Newswire PDF Print

An earnings surprise is the calculated difference between a firm’s expected earnings numbers provided by Wall Street analysts and the actual reported numbers. A significant surprise factor often triggers sharp movements in the share price following the earnings release. For the most recent quarter, Rockwell Medical, Inc. (NASDAQ:RMTI) reported earnings per share of $-0.05 for the fiscal period ending on 2015-06-30, an earnings surprise factor of 50%. The actual number was $0.05 away from the brokerage firm consensus estimates. The sales surprise factor in per share dollar terms was $2.096 for the most recent quarter or 19.3%.

Rockwell Medical, Inc. (NASDAQ:RMTI) is next scheduled to report quarterly earnings on 2015-11-09. Sell-side brokerages are expecting the company to report earnings of $0.09 per share, according to the 6 covering analysts that were polled by Zacks Research. Shareholders will be closely monitoring how the estimates fluctuate leading up to the expected report date.

In terms of price targets, sell-side brokerage firms are projecting that the stock will reach the range of $4-26. The average number taken from the 6 surveyed analysts, often referred to as the consensus price target, stands at $15. Using a simplified 1 to 5 rating system produces a score of 2.55 for Rockwell Medical, Inc., where 1 represents a Strong Buy rating and 5 would indicate a Strong Sell rating. In taking a look at the recent analyst sentiment, three months ago the rating mean stood at 2.55. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.


Smoking Ups Risk of Some Renal Cell Carcinoma Subtypes - Monthly Prescribing Reference (registration) PDF Print
August 17, 2015 Renal Cell Carcinoma Subtypes
Renal Cell Carcinoma Subtypes

(HealthDay News) — Smoking is a risk factor for clear cell and papillary renal cell carcinoma, but not for the chromophobe subtype, according to a study published in the September issue of The Journal of Urology.

Neel H. Patel, MD, from the State University of New York in Buffalo, and colleagues examined the correlation between smoking and renal cell carcinoma subtype. Data were collected from 816 patients with nonfamilial renal cell carcinoma (705) or benign pathology (111) undergoing nephrectomy.

The researchers found that 51% of patients reported smoking, including 21% active smokers and 30% former smokers. Compared with benign histology, active smoking was more common with clear cell or papillary cell carcinoma (23 and 26%, respectively, vs. 14%; P<0.05 each). Active smoking was less common with chromophobe renal cell carcinoma (6%; P<0.05 vs. clear cell or papillary). Any smoking history was also less common with chromophobe vs. clear cell or papillary histology (26% vs. 53% [P=0.003] or 58% [P=0.001]). For clear cell and papillary histologies, but not chromophobe histology, independent associations with active smoking persisted after multivariable adjustment (odds ratios, 2.2 and 2.4, respectively; both P<0.05).

"These findings underscore distinct carcinogenic mechanisms underlying the various renal cell carcinoma subtypes," the authors write.

Full Text (subscription or payment may be required)


3 Stocks Pulling The Health Care Sector Downward - TheStreet.com PDF Print

3 Stocks Pulling The Health Care Sector Downward
KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $25.5 ...

and more »


Research and Markets: Metastatic Renal Cell Cancer Pipeline Insights 2015 ... - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s32np9/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Cancer-Pipeline Insights" report to their offering.


Metastatic Renal Cell Cancer- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Metastatic Renal Cell Cancer. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Metastatic Renal Cell Cancer Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Metastatic Renal Cell Cancer- Pipeline Insights Report covers the Metastatic Renal Cell Cancer pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Metastatic Renal Cell Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.


  • The report provides a Metastatic Renal Cell Cancer Landscape across the globe
  • The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
  • Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • Pipeline products coverage based on various stages of development from NDA filings to discovery.
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  • Metastatic Renal Cell Cancer Overview
  • Metastatic Renal Cell Cancer Pipeline Therapeutics
  • Metastatic Renal Cell Cancer Therapeutics under Development by Companies
  • Metastatic Renal Cell Cancer Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Metastatic Renal Cell Cancer Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Metastatic Renal Cell Cancer Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Metastatic Renal Cell Cancer Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Metastatic Renal Cell Cancer - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metastatic Renal Cell Cancer - Discontinued Products
  • Metastatic Renal Cell Cancer - Dormant Products
  • Companies Involved in Therapeutics Development for Metastatic Renal Cell Cancer

For more information visit http://www.researchandmarkets.com/research/s32np9/metastatic_renal


In Jos: Controlled diabetes, hypertension can curb onset of renal failure - Pulse Nigeria PDF Print

A specialist in internal medicine, Dr Yiliji Kumtap, has said that renal diseases and failures, prominent in hypertensive and diabetic patients, can be curtailed if effectively managed.

Kumtap told the News Agency of Nigeria(NAN) in Jos on Monday that most patients suffering from hypertension and diabetes could develop renal disease and eventually renal failure in not controlled.

He identified two types of renal failures as acute and chronic, saying that acute renal failure usually occurred suddenly.

"It is the sudden loss of the kidney function which occurs within days or weeks. On its part, chronic renal failure is in stages; it starts from a decrease in the glomerular filtration rate.

"As the kidney function declines, waste products can build up in the blood, causing a condition known as uremia,'' he said.

He added that the symptoms included fatigue, fluid retention, swelling, changes in urine colour and sleeping disorder while kidney pain could be felt in the back.

He advised that ? patients with high blood pressure and are diabetic should stick to their doctor's advice.

"Patients who are hypertensive and diabetic should ensure that they go for regular medical checkups, do regular exercises and control their diets.

"They should also take their routine drugs as and when prescribed," he said.

He also advised such persons to take lots of water as that could control and prevent kidney diseases such as kidney stones.

Kumtap advised the public to inculcate regular medical checkups to enable experts to diagnosise any kidney issue at an early stage when it could be treated or effectively managed.


<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 14 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.